BioSpace News Archive

In a challenging macroeconomic environment, 3M executed well and delivered solid earnings, while continuing to drive growth through investments in large, fast-growing areas.

IVERIC bio, Inc. announced that it has entered into a term loan debt financing facility with Hercules Capital, Inc. and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.

IVERIC bio, Inc. announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update.

Kelun-Biotech announced that it has entered into a collaboration and exclusive license agreement with MSD, to develop an investigational antibody drug conjugate for the treatment of solid tumors.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced that it plans to release 2022 second quarter financial and operating results after the market closes on Monday, August 8, 2022.

Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the enrolment of the first five patients into the International Wilson’s Disease Patient Registry (“iWD Registry”), the first global registry of patients with Wilson’s Disease.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022 before the open of the U.S. financial markets.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted three employees nonqualified stock options to purchase an aggregate of 29,200 shares of its common stock with an exercise price of $2.68, which is equal to the closing price of Gritstone’s common stock on July 15, 2022, the last trading day preceding the grant date of the awards.